Cyclophosphamide: all 1,616 studies that test it

Page 9 of 17. Open to participants first (256), then studies with results posted, then the rest; newest registration first within each.

• Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate CancerActive, not recruitingNCT05479578Phase 1
• Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome.Active, not recruitingNCT05457010Phase 1
• Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic LeukemiaActive, not recruitingNCT05453500Phase 2
• A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)Active, not recruitingNCT05406401Phase 2
• ......SMARTEST Trial......CompletedNCT05380713Phase 2
• Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell TransplantsActive, not recruitingNCT05364762Phase 2
• Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLLStatus unknownNCT05322733Phase 2
• Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLLStatus unknownNCT05287984Phase 2
• A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast CancerActive, not recruitingNCT05275777Phase 1/2
• Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian CancerTerminatedNCT05243524Phase 2
• A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell LymphomaStatus unknownNCT05200312Phase 2
• Personalized DC Vaccines in Non Small Cell Lung CancerActive, not recruitingNCT05195619Phase 1
• Comparison of PT-Cy at a Dose of 25 mg/kg/Day and PT-Cy at a Dose of 50 mg/kg/Day in GVHD ProphylaxisStatus unknownNCT05158608Phase 3
• GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATGActive, not recruitingNCT05153226Phase 3
• A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal ImpairmentStatus unknownNCT05147493Phase 2
• Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted GraftActive, not recruitingNCT05088356Phase 1
• Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid TumorsActive, not recruitingNCT05075993Phase 1
• Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.Status unknownNCT05049473Phase 2
• TriPRIL CAR T Cells in Multiple MyelomaActive, not recruitingNCT05020444Phase 1
• Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple MyelomaStatus unknownNCT05008536Early Phase 1
• A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk RhabdomyosarcomaActive, not recruitingNCT04994132Phase 3
• A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8)WithdrawnNCT04974996Phase 1
• A Study of N9 Chemotherapy in Children With NeuroblastomaActive, not recruitingNCT04947501Early Phase 1
• Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid MalignanciesCompletedNCT04943757Phase 2
• A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian TumorsActive, not recruitingNCT04931342Phase 2
• HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation CyclophosphamideActive, not recruitingNCT04904588Phase 2
• Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast CancerActive, not recruitingNCT04895761Phase 1
• GFRα4 CAR T Cells in MTC PatientsActive, not recruitingNCT04877613Phase 1
• A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow TransplantActive, not recruitingNCT04872595Phase 2
• A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)TerminatedNCT04790903Phase 1
• Chlorpheniramine Maleate Nasal Spray for Chronic RhinitisWithdrawnNCT04790487Phase 2/3
• A 3 Arm Randomized Study on Health-related QoL of Elderly Patients With Advanced Soft Tissue SarcomaTerminatedNCT04780464Phase 3
• Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe HemoglobinopathiesWithdrawnNCT04776850Early Phase 1
• A Prospective Study of Cyclophosphamide Treatment for Idiopathic Retroperitoneal FibrosisStatus unknownNCT04762810Phase 4
• The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast CancerStatus unknownNCT04753177Phase 2/3
• A Phase 1 Study of ADI-001 in B Cell MalignanciesTerminatedNCT04735471Phase 1
• Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Acute B Lymphocytic LeukemiaStatus unknownNCT04714593Phase 1/2
• A Phase 2 Trial for Patients With Metastatic Solid CancerActive, not recruitingNCT04713371Phase 2
• Novel BCMA-targeted CAR-T Cell Therapy for Multiple MyelomaStatus unknownNCT04706936Phase 1
• Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHLActive, not recruitingNCT04697940Phase 1/2
• Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell CarcinomaActive, not recruitingNCT04696731Phase 1
• CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma.Active, not recruitingNCT04667663Phase 1
• Cabozantinib With Topotecan-CyclophosphamideCompletedNCT04661852Phase 1
• Neoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer PatientsCompletedNCT04659551Phase 2
• Low Dose Continuous Cyclophosphamide vs Standard Doxorubicin in Advanced Sarcoma Elderly PatientsTerminatedNCT04656262Phase 3
• CAR-T Cells for HIV InfectionActive, not recruitingNCT04648046Phase 1/2
• CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)Active, not recruitingNCT04637763Phase 1
• CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic LeukemiaStatus unknownNCT04626765Early Phase 1
• CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple MyelomaStatus unknownNCT04626752Early Phase 1
• CAR-T Cells in Treating Patients With Relapsed or Refractory NHLStatus unknownNCT04626739Early Phase 1
• Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell TransplantationStatus unknownNCT04626726Early Phase 1
• NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDSActive, not recruitingNCT04623944Phase 1
• Cyclophosphamide in the Treatment of Refractory Proliferative Arachnoiditis in CNS TuberculosisStatus unknownNCT04620772Phase 2/3
• Comparison of BTD and BCD Based Regimens in the Treatment of AL AmyloidosisStatus unknownNCT04612582Phase 4
• ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple MyelomaWithdrawnNCT04579523Phase 1
• Mesothelin-targeted CAR T-cell Therapy in Patients With MesotheliomaActive, not recruitingNCT04577326Phase 1
• Liposomal Mitoxantrone Hydrochloride Injection,Cyclophosphamide, Vincristine and Prednisone in the Treatment of PTCLTerminatedNCT04548700Phase 1
• A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological MalignanciesActive, not recruitingNCT04547049Phase 3
• Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, GD2-CAR PERSIST TrialSuspendedNCT04539366Phase 1
• Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal CancerCompletedNCT04534218Phase 2
• Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in AdultsActive, not recruitingNCT04530565Phase 3
• Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell LymphomaActive, not recruitingNCT04480099Phase 2
• Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated LymphomaActive, not recruitingNCT04479267Phase 2
• VR-CAP in the First-line Treatment for Patients With Marginal Zone LymphomaCompletedNCT04433156Phase 2
• Comparison between2 Drugs in Lupus NephritisCompletedNCT04424602Phase 4
• Iberdomide Combined With Low-dose Cyclophosphamide and DexamethasoneActive, not recruitingNCT04392037Phase 2
• Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic CancerActive, not recruitingNCT04390399Phase 2
• TBI Using IMRT and Cyclophosphamide Prior to Stem Cell Transplant for the Treatment of Severe Systemic SclerosisActive, not recruitingNCT04380831Early Phase 1
• Reduced Intensity Transplantation for Severe Sickle Cell DiseaseActive, not recruitingNCT04362293Phase 2
• NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBCActive, not recruitingNCT04335669Phase 3
• "Cocktail" Therapy for Hepatitis B Related Hepatocellular CarcinomaStatus unknownNCT04317248Phase 2
• Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast CancerActive, not recruitingNCT04290793Phase 2/3
• CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic MalignanciesWithdrawnNCT04282174Phase 2
• Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic MalignanciesStatus unknownNCT04264078Early Phase 1
• Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute LeukemiaActive, not recruitingNCT04262843Phase 2
• The CAPER Trial: A Phase Ib Clinical Trial of Cyclophosphamide And PEmbrolizumab in Metastatic Renal Cell CarcinomaStatus unknownNCT04262427Phase 1/2
• Study of Pomalidomide, Oral Dexamethasone and Very Low-dose Cyclophosphamide in Patients With Refractory Multiple Myeloma Who Have Received Lenalidomide and BortezomibTerminatedNCT04243109Phase 2
• 9-ING-41 in Pediatric Patients With Refractory Malignancies.TerminatedNCT04239092Phase 1
• Phase II Study of Neoadjuvant Weekly Paclitaxel and Carboplatin Followed by Dose Dense Epirubicin and Cyclophosphamide in Stage II and III Triple Negative Breast CancerCompletedNCT04224922Phase 2
• CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell MalignanciesActive, not recruitingNCT04214886Phase 1
• DCV in the Treatment of Recurrence and Refractory Childhood Solid TumorsStatus unknownNCT04213612Phase 1
• ATG Plus PTCy vs ATG for CGVHD ProphylaxisActive, not recruitingNCT04202835Phase 2
• Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-CancerCompletedNCT04187898Phase 1
• Study of alloCART-19 Cell Therapy in Pediatric Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic LeukemiaActive, not recruitingNCT04173988Early Phase 1
• Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary DiseaseActive, not recruitingNCT04166565Phase 2
• Autologous Transplant Targeted Against Crohn'sWithdrawnNCT04154735Phase 2
• Non-Viral TCR Gene TherapyWithdrawnNCT04102436Phase 2
• T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR)WithdrawnNCT04093648Phase 1
• A Phase 2 Trial for Men With Metastatic Prostatic AdenocarcinomaCompletedNCT04090775Phase 2
• Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast CancerActive, not recruitingNCT04083963Phase 2
• COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast CancerWithdrawnNCT04038489Phase 2
• CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma.Status unknownNCT04037566Phase 1
• Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain TumorsCompletedNCT04023669Phase 1
• Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid TumorsTerminatedNCT03992326Phase 1
• Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic LeukemiaCompletedNCT03991884Phase 1
• Optimizing PTCy Dose and TimingActive, not recruitingNCT03983850Phase 1/2
• BCD Regimen in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD)Status unknownNCT03982771Phase 2
• Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid TumorsActive, not recruitingNCT03967223Phase 2
• Exploring Durable Remission With Rituximab in Antineutrophil Cytoplasmic Antibody(ANCA)-Associated VasculitisStatus unknownNCT03942887Phase 3
• Cyclophosphamide in the Treatment of Associated Acquired Lipodystrophy Syndrome With Type 1 DiabetesActive, not recruitingNCT03936829Not applicable

← Cyclophosphamide overview